Molecular Diagnosis of Hepatocellular Carcinoma in Egypt | ||||
| Research Journal of Applied Biotechnology | ||||
| Article 4, Volume 1, Issue 1, June 2015, Page 44-53 PDF (374.65 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/rjab.2015.53512 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Ahmed A. Raouf* 1; Iman A. Gaweesh2; Hanaa M. Badran* 3; Manal El-Hamshary4; Mohammed S. Abdou* 2 | ||||
| 1Department of Clinical Biochemistry,National Liver Institute | ||||
| 2Department of Clinical Pathology, National Liver Institute | ||||
| 3Department of Hepatology, National Liver Institute | ||||
| 4Department of Molecular Diagnostics, Genetic Engineering and Biotechnology Research Institute - University of Sadat City, Egypt | ||||
| Abstract | ||||
| Background: Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. It is a prevalent cancer that often develops in patients with chronic hepatitis and cirrhosis in association with hepatitis B or C virus infection. Diagnostic modalities such as tumor markers, ultrasonography and CT have contributed to its earlier diagnosis but remain not sensitive enough. Telomeres are specializes structures at the ends of eukaryotic chromosomes and lead to their stabilization. Telomerase is a ribonucleoprotein enzyme responsible for replication of telomeres at chromosomal ends in most eukaryotes.Its RNA subunit provides the template for addition of (GGTTAG) repeats to chromosome ends .Human telomerase mRNA (hTERT- mRNA)has been identified in many cancers and claimed to be reactivated in HCC. Aim: to investigate Human telomerase mRNA (hTERT- mRNA) in peripheral blood of hepatocellular carcinoma (HCC) and chronic liver diseases (CLD) patients,To correlate the level of Human telomerase mRNA (hTERT- mRNA) with alpha feto –protein ( AFP),the traditional serological marker for HCC. Patients and methods:The study was conducted on 60 patients selected from the National Liver Institute clinics and inpatients hepatology department. The patients were divided into group I (30 patients with CLD) and group II (30 patients diagnosed to have HCC). In addition to group III that comprised 20 apparantly healthy volunteers .All selected individuals were subjected to history taking ,thorough clinical examination, abdominal ultrasonography and routine laboratory investigations as liver function tests ,CBC, hepatitis viral markers , serum AFP and quantitative detection of m-RNA expression encoding for telomerase catalytic subunit hTERT by real time PCR measurement using 7500 Real Time PCR System(Applied Biosystems). Results: A significant elevation in AFP level in HCC group when compared to CLD patients group or to control group (p < 0.01).The mean level of hTERT m-RNA expression in HCC patients group was significantly higher than both CLD patients group and controls (p<0.01). An hTERT m-RNA expression cut off level of 81.5 copies /ml showed prediction of HCC 100% sensitivity,95 % specificity, accuracy 99.6% ,standard error (SE) was 0.003 and confidence interval (CI) was (0.99- Conclusion: Real time assay of hTERT m-RNA in patients with CLD could be used as a satisfactory molecular marker for diagnosis of HCC. hTERT m-RNA is thought to be superior to AFP for early detection of HCC. | ||||
| Keywords | ||||
| Diagnostics; HCC; AFP level; hTERT m-RNA | ||||
| References | ||||
|
Santamaria E, Muñoz J, Fernández-Irigoyen J, Prìeto J and Corrales F Toward the discovery of new biomarkers of hepatocellular carcinoma by proteomics. Liver Int; 27(2) :163-
Yu AS and Keeffe EB (2003): Management of hepatocellular carcinoma. Rev Gastrenterol Disord ;3: 8-
Cairney C and Keith W (2008): Telomerase redefined: Integrated regulation of hTR and hTERT for telomere maintenance and telomerase activity. Biochimie; 90(1) :13-
Karlseder J, Smogorzewska A and de Lange T (2002): Senescence induced by altered telomere state; not telomere loss. Science; 295 :2446 –
Suda T, Isokawa O, Aoyagi Y, Nomoto M, Tsukada K, Shimizu T, Suzuki Y, Naito A, Igarashi H, Yanagi M, Takahashi T and Asakura H (1998): Quantitation of telomerase activity in hepatocellular carcinoma: A possible aid for a prediction of recurrent diseases in the remnant liver. Hepatology; 27 :402–
Shay JW and Wright WE (2002): Hayflick, his limit, and cellular ageing. Mol Cell Biol.; 1 :72-
Wu W, Yao DF, Qiu LW, Wu XH, Yao M, Su XQ, and Zou L (2005): Abnormal expression of hepatomas and circulating telomerase and its clinical values. Hepatobiliary Pancreat Dis Int; 4(4) :544-
Miura N, Maeda Y, Kanbe T, Yazama H, Takeda Y, Sato R, Tsukamoto T, Sato E, Marumoto A, Harada T, Sano A, Kishimoto Y, Hirooka Y, Murawaki Y, Hasegawa J and Shiota G (2005): Serum h-TERT messenger RNA as a novel tumor marker for hepatocellular carcinoma. Clin Cancer Res; 11 :3205-
Chiappini F.(2012): Circulating Tumor CellsMeasurements in
Hepatocellular Carcinoma. International Journal of Hepatology, Volume 012, Article ID 684802, 16 pages doi:10.1155/2012/684802.
(10a) Zhou L, J. Liu, and F. Luo, (2006) :Serum tumor markers for detection of hepatocellular carcinoma,” World Journal of Gastroenterology, vol , no 8, pp. 1175– ,
(10b) Wang YL, G. Li, D. Wu, Y. W. Liu, and Z. Yao,(2007): Analysis of alpha-fetoprotein mRNA level on the tumor cell hematogenous spread of patients with hepatocellular carcinoma undergoing orthotopic liver transplantation,”
53
Research Journal of Applied Biotechnology (RJAB)
Transplantation Proceedings, vol. 39, no. 1, pp. 166– ,
(10c) Grizzi F, B. Franceschini, C. Hamrick, E. E. Frezza, E. Cobos, andM
Chiriva-Internati,(2007): Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma,” Journal of Translational Medicine,vol. 5, article no. 3, 2007.
Joyce M.J. Houben, Harald J.J. Moonen, Frederik J. van Schooten and Geja J. Hageman (2007): Telomere length assessment: Biomarker of chronic oxidative stress. Free Radical Biology and Medicine; 44 :235-
)Deng-Fu Yao, Zhi-Zhen Dong and Min Yao (2007): Specific molecular markers in HCC. Hepatobiliary Pancreat Dis Int; 6(3) :15-
Kong SY, J W Park, J O Kim “Alpha-fetoprotein and human telomerase reverse transcriptase mRNA levels in peripheral blood of patients with hepatocellular carcinoma,” Journal of Cancer Research and Clinical Oncology, vol. 135, no. 8, pp. 1091– ,
(14a) Miura N, Maruyama S, Oyama K, Horie Y, Kohno M, Noma E, Sakaguchi S, Nagashima M, Kudo M, Kishimoto Y, Kawasaki H, Hasegawa J and Shiota G (2007): Development of a novel assay to quantify serum TERT messenger RNA and its significance as a tumor marker for hepatocellular carcinoma.
(14b) Tatsuma T, Goto S, Kitano S, Lin YC, Lee CM and Chen C (2000) : Telomerase activity in the peripheral blood for diagnosis of hepatoma. J. Gastroenter. Hepatol.; 15 :1064–
Miura N, Shiota G, Nakagawa T, Maeda Y, Sano A, Marumoto A, Kishimoto Y, Murawaki Y and Hasegawa J Sensitive detection of human telomerase reverse transcriptase mRNA in the serum of patients with hepatocellular carcinoma. Oncology; 64 :430-
) Murashima M, Tanaka M, Haramaki M, Yutani S, Nakashima Y, Harada K, Ide T, Kumashiro R and Sata M (200 A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP. Dig Dis Sci.; 51(4) :808-
Attiya HM, Gehan K El-Saeed, Iman A G, Maha AEl-Basiouny, Hala H El-Saeed.,. Mohamed A Soliman (2008):Molecular detection of telomerase m-RNA in the peripheral blood of patients with hepatocellular carcinoma .MD Thesis, Menofiya University.
) Miura N, Yukio Osaki, Miki Nagashima, Michimori Kohno, Kensho Yorozu, Kohei Shomori, Takamasa Kanbe, Kenji Oyama, Yukihiro Kishimoto, Shigeo Maruyama, Eijiro Noma, Yutaka Horie, Masatoshi Kudo,SeigoSakaguchi,Yasuaki Hasegawa and Goshi Shiota (2010): h-TERT m-RNA as a novel biomarker for early detection of hepatoma
Gastroenterology 2010,10:46. | ||||
|
Statistics Article View: 202 PDF Download: 273 |
||||
